257 related articles for article (PubMed ID: 22375031)
1. Activation of GATA binding protein 6 (GATA6) sustains oncogenic lineage-survival in esophageal adenocarcinoma.
Lin L; Bass AJ; Lockwood WW; Wang Z; Silvers AL; Thomas DG; Chang AC; Lin J; Orringer MB; Li W; Glover TW; Giordano TJ; Lam WL; Meyerson M; Beer DG
Proc Natl Acad Sci U S A; 2012 Mar; 109(11):4251-6. PubMed ID: 22375031
[TBL] [Abstract][Full Text] [Related]
2. GATA binding protein 6 (GATA6) is co-amplified with PIK3CA in patients with esophageal adenocarcinoma and is linked to neoadjuvant therapy.
Plum PS; Löser H; Zander T; Essakly A; Bruns CJ; Hillmer AM; Alakus H; Schröder W; Büttner R; Gebauer F; Quaas A
J Cancer Res Clin Oncol; 2021 Apr; 147(4):1031-1040. PubMed ID: 33300112
[TBL] [Abstract][Full Text] [Related]
3. The characterization of an intestine-like genomic signature maintained during Barrett's-associated adenocarcinogenesis reveals an NR5A2-mediated promotion of cancer cell survival.
Duggan SP; Behan FM; Kirca M; Zaheer A; McGarrigle SA; Reynolds JV; Vaz GM; Senge MO; Kelleher D
Sci Rep; 2016 Sep; 6():32638. PubMed ID: 27586588
[TBL] [Abstract][Full Text] [Related]
4. Identification of Subtypes of Barrett's Esophagus and Esophageal Adenocarcinoma Based on DNA Methylation Profiles and Integration of Transcriptome and Genome Data.
Jammula S; Katz-Summercorn AC; Li X; Linossi C; Smyth E; Killcoyne S; Biasci D; Subash VV; Abbas S; Blasko A; Devonshire G; Grantham A; Wronowski F; O'Donovan M; Grehan N; Eldridge MD; Tavaré S; ; Fitzgerald RC
Gastroenterology; 2020 May; 158(6):1682-1697.e1. PubMed ID: 32032585
[TBL] [Abstract][Full Text] [Related]
5. Hypomethylation of noncoding DNA regions and overexpression of the long noncoding RNA, AFAP1-AS1, in Barrett's esophagus and esophageal adenocarcinoma.
Wu W; Bhagat TD; Yang X; Song JH; Cheng Y; Agarwal R; Abraham JM; Ibrahim S; Bartenstein M; Hussain Z; Suzuki M; Yu Y; Chen W; Eng C; Greally J; Verma A; Meltzer SJ
Gastroenterology; 2013 May; 144(5):956-966.e4. PubMed ID: 23333711
[TBL] [Abstract][Full Text] [Related]
6. Progression of Barrett's metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation.
Kimchi ET; Posner MC; Park JO; Darga TE; Kocherginsky M; Karrison T; Hart J; Smith KD; Mezhir JJ; Weichselbaum RR; Khodarev NN
Cancer Res; 2005 Apr; 65(8):3146-54. PubMed ID: 15833844
[TBL] [Abstract][Full Text] [Related]
7. Widespread hypomethylation occurs early and synergizes with gene amplification during esophageal carcinogenesis.
Alvarez H; Opalinska J; Zhou L; Sohal D; Fazzari MJ; Yu Y; Montagna C; Montgomery EA; Canto M; Dunbar KB; Wang J; Roa JC; Mo Y; Bhagat T; Ramesh KH; Cannizzaro L; Mollenhauer J; Thompson RF; Suzuki M; Meltzer SJ; Melnick A; Greally JM; Maitra A; Verma A
PLoS Genet; 2011 Mar; 7(3):e1001356. PubMed ID: 21483804
[TBL] [Abstract][Full Text] [Related]
8. High Content Imaging of Barrett's-Associated High-Grade Dysplasia Cells After siRNA Library Screening Reveals Acid-Responsive Regulators of Cellular Transitions.
Phipps SM; Garry CE; Kamal S; Johnson JD; Gilmer J; Long A; Kelleher D; Duggan SP
Cell Mol Gastroenterol Hepatol; 2020; 10(3):601-622. PubMed ID: 32416156
[TBL] [Abstract][Full Text] [Related]
9. Hypermethylation of the AKAP12 promoter is a biomarker of Barrett's-associated esophageal neoplastic progression.
Jin Z; Hamilton JP; Yang J; Mori Y; Olaru A; Sato F; Ito T; Kan T; Cheng Y; Paun B; David S; Beer DG; Agarwal R; Abraham JM; Meltzer SJ
Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):111-7. PubMed ID: 18199717
[TBL] [Abstract][Full Text] [Related]
10. GATA6 expression in Barrett's oesophagus and oesophageal adenocarcinoma.
Pavlov K; Honing J; Meijer C; Boersma-van Ek W; Peters FT; van den Berg A; Karrenbeld A; Plukker JT; Kruyt FA; Kleibeuker JH
Dig Liver Dis; 2015 Jan; 47(1):73-80. PubMed ID: 25445407
[TBL] [Abstract][Full Text] [Related]
11. Integrative genomics identified RFC3 as an amplified candidate oncogene in esophageal adenocarcinoma.
Lockwood WW; Thu KL; Lin L; Pikor LA; Chari R; Lam WL; Beer DG
Clin Cancer Res; 2012 Apr; 18(7):1936-46. PubMed ID: 22328562
[TBL] [Abstract][Full Text] [Related]
12. Isoforms of RNF128 Regulate the Stability of Mutant P53 in Barrett's Esophageal Cells.
Ray D; Ray P; Ferrer-Torres D; Wang Z; Nancarrow D; Yoon HW; San Martinho M; Hinton T; Owens S; Thomas D; Jiang H; Lawrence TS; Lin J; Lagisetty K; Chang AC; Beer DG
Gastroenterology; 2020 Feb; 158(3):583-597.e1. PubMed ID: 31715145
[TBL] [Abstract][Full Text] [Related]
13. Bile acid exposure up-regulates tuberous sclerosis complex 1/mammalian target of rapamycin pathway in Barrett's-associated esophageal adenocarcinoma.
Yen CJ; Izzo JG; Lee DF; Guha S; Wei Y; Wu TT; Chen CT; Kuo HP; Hsu JM; Sun HL; Chou CK; Buttar NS; Wang KK; Huang P; Ajani J; Hung MC
Cancer Res; 2008 Apr; 68(8):2632-40. PubMed ID: 18413730
[TBL] [Abstract][Full Text] [Related]
14. GATA4 blocks squamous epithelial cell gene expression in human esophageal squamous cells.
Stavniichuk R; DeLaForest A; Thompson CA; Miller J; Souza RF; Battle MA
Sci Rep; 2021 Feb; 11(1):3206. PubMed ID: 33547361
[TBL] [Abstract][Full Text] [Related]
15. Subtypes of Barrett's oesophagus and oesophageal adenocarcinoma based on genome-wide methylation analysis.
Yu M; Maden SK; Stachler M; Kaz AM; Ayers J; Guo Y; Carter KT; Willbanks A; Heinzerling TJ; O'Leary RM; Xu X; Bass A; Chandar AK; Chak A; Elliott R; Willis JE; Markowitz SD; Grady WM
Gut; 2019 Mar; 68(3):389-399. PubMed ID: 29884612
[TBL] [Abstract][Full Text] [Related]
16. A Transcriptional Regulatory Loop of Master Regulator Transcription Factors, PPARG, and Fatty Acid Synthesis Promotes Esophageal Adenocarcinoma.
Ma S; Zhou B; Yang Q; Pan Y; Yang W; Freedland SJ; Ding LW; Freeman MR; Breunig JJ; Bhowmick NA; Pan J; Koeffler HP; Lin DC
Cancer Res; 2021 Mar; 81(5):1216-1229. PubMed ID: 33402390
[TBL] [Abstract][Full Text] [Related]
17. Systems Biology Analyses Show Hyperactivation of Transforming Growth Factor-β and JNK Signaling Pathways in Esophageal Cancer.
Blum AE; Venkitachalam S; Ravillah D; Chelluboyina AK; Kieber-Emmons AM; Ravi L; Kresak A; Chandar AK; Markowitz SD; Canto MI; Wang JS; Shaheen NJ; Guo Y; Shyr Y; Willis JE; Chak A; Varadan V; Guda K
Gastroenterology; 2019 May; 156(6):1761-1774. PubMed ID: 30768984
[TBL] [Abstract][Full Text] [Related]
18. Genomic profiling identifies GATA6 as a candidate oncogene amplified in pancreatobiliary cancer.
Kwei KA; Bashyam MD; Kao J; Ratheesh R; Reddy EC; Kim YH; Montgomery K; Giacomini CP; Choi YL; Chatterjee S; Karikari CA; Salari K; Wang P; Hernandez-Boussard T; Swarnalata G; van de Rijn M; Maitra A; Pollack JR
PLoS Genet; 2008 May; 4(5):e1000081. PubMed ID: 18535672
[TBL] [Abstract][Full Text] [Related]
19. The miR-106b-25 polycistron, activated by genomic amplification, functions as an oncogene by suppressing p21 and Bim.
Kan T; Sato F; Ito T; Matsumura N; David S; Cheng Y; Agarwal R; Paun BC; Jin Z; Olaru AV; Selaru FM; Hamilton JP; Yang J; Abraham JM; Mori Y; Meltzer SJ
Gastroenterology; 2009 May; 136(5):1689-700. PubMed ID: 19422085
[TBL] [Abstract][Full Text] [Related]
20. Chromosomal abnormalities and novel disease-related regions in progression from Barrett's esophagus to esophageal adenocarcinoma.
Akagi T; Ito T; Kato M; Jin Z; Cheng Y; Kan T; Yamamoto G; Olaru A; Kawamata N; Boult J; Soukiasian HJ; Miller CW; Ogawa S; Meltzer SJ; Koeffler HP
Int J Cancer; 2009 Nov; 125(10):2349-59. PubMed ID: 19670330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
